Cary Street Partners Investment Advisory’s ARK Genomic Revolution ETF ARKG Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-437	Closed	-$12.2K	–	700
2023 Q3	$12.2K	Hold	437	–	–	﹤0.01%	1239
2023 Q2	$14.9K	Buy	437 +95	+28%	+$2.99K	﹤0.01%	1130
2023 Q1	$10.3K	Sell	342 -70	-17%	-$2.17K	﹤0.01%	1142
2022 Q4	$11.6K	Buy	+412	New	+$13.1K	﹤0.01%	1110
2020 Q4	–	Sell	-143	Closed	-$9K	–	380
2020 Q3	$9K	Buy	+143	New	+$8.38K	﹤0.01%	773

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Main Management San Francisco, California $1.37B AUM 19.06% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Cary Street Partners Investment Advisory's ARKG Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2023, closing a stake of 437 shares — an estimated $12.2K sold.

Cary Street Partners Investment Advisory first reported a position in ARKG in Q3 2020 and held it in 5 quarters. The position peaked at $14.9K in Q2 2023. 300 funds tracked by Wall St. Rank hold ARKG as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining ARK Genomic Revolution ETF position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 437 ARK Genomic Revolution ETF shares in Q4 2023, an estimated $12.2K.
Cary Street Partners Investment Advisory first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 5 quarters.
Cary Street Partners Investment Advisory's ARK Genomic Revolution ETF position peaked at $14.9K in Q2 2023.
300 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.